Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Exo-1 (Exo1) is a novel, potent and reversible inhibitor of exocytosis which is used as a chemical inhibitor of the exocytic pathway. Golgi ARF 1 (ADP-Ribosylation Factor) GTPase is activated as a result of it. Exo1 triggers a swift collapse of the Golgi apparatus to the endoplasmic reticulum, thereby sharply impeding the traffic that emerges from the latter. Exo1 causes ADP-ribosylation factor (ARF) 1 to be released from Golgi membranes quickly, much like Brefeldin A (BFA), but it has less of an impact on how the trans-Golgi network is organized. Exo1 functions via a distinct pathway than BFA. Exo1 does not, in contrast to BFA, cause CtBP/Bars50 to become ADP-ribosylated or obstruct the function of guanine nucleotide exchange factors that are particular to Golgi-based ARFs. Consequently, Exo1 permits the separation of Bars50's fatty acid exchange activity from ARF1 activity in the regulation of Golgi tubulation.
Targets |
exocytosis; Golgi; ARF-1
|
---|---|
ln Vitro |
Exo1 modifies the GTPase activity of Golgi ARF1. Exo1 offers a separate method of interfering with Golgi activity because it blocks a portion of the membrane events that BFA blocks, although it appears to target a different protein target and likely has different side effects. Exo1 Disrupts Golgi structures to disrupt vesicular traffic from the ER to the Golgi apparatus. Exo1 has an IC50 of about 20 μM, which inhibits exocytosis. Exo1 inhibits newly synthesized proteins like VSVGts-GFP, transferrin, and MHC class I from acquiring endoglycosidase H resistance[1].
|
References |
Molecular Formula |
C15H12FNO3
|
|
---|---|---|
Molecular Weight |
273.26
|
|
Exact Mass |
273.08
|
|
Elemental Analysis |
C, 65.93; H, 4.43; F, 6.95; N, 5.13; O, 17.56
|
|
CAS # |
75541-83-2
|
|
Appearance |
Solid powder
|
|
SMILES |
COC(=O)C1=CC=CC=C1NC(=O)C2=CC=C(C=C2)F
|
|
InChi Key |
KIAPWMKFHIKQOZ-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C15H12FNO3/c1-20-15(19)12-4-2-3-5-13(12)17-14(18)10-6-8-11(16)9-7-10/h2-9H,1H3,(H,17,18)
|
|
Chemical Name |
methyl 2-[(4-fluorobenzoyl)amino]benzoate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6595 mL | 18.2976 mL | 36.5952 mL | |
5 mM | 0.7319 mL | 3.6595 mL | 7.3190 mL | |
10 mM | 0.3660 mL | 1.8298 mL | 3.6595 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04491240 | Completed | Drug: EXO 1 inhalation Drug: EXO 2 inhalation |
Covid19 COVID-19 |
State-Financed Health Facility "Samara Regional Medical Center Dinasty" |
July 20, 2020 | Phase 1 Phase 2 |
Exit of VSVGts-GFP from the ER is inhibited by Exo1. Exo1 does not induce the ADP-ribosylation of Bars50.Proc Natl Acad Sci U S A.2003 May 27;100(11):6469-74. td> |
Exo1 induces tubulation and collapse of the Golgi apparatus but not endosomes and TGN. td> |
Exo1 acts on ARF1-GTPase through a different mechanism compared with BFA.Proc Natl Acad Sci U S A.2003 May 27;100(11):6469-74. td> |